Q-omics provides the consensus-scored CBX3P4 profile across patient tissues and cancer cell-line models. CBX3P4 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CBX3P4 is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, CBX3P4 RNA expression shows 18,876 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, THCA, and UVM as cancer lineages where CBX3P4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CBX3P4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CBX3P4 survival associations across molecular data types. CBX3P4 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CBX3P4 RNA expression–survival associations across cancer types. High CBX3P4 expression shows unfavorable associations in KIRC, COAD and CESC, but favorable associations in BLCA, PAAD and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CBX3P4 RNA expression.
This table summarizes CBX3P4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for CBX3P4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CBX3P4 shows lower tumor expression in THCA and KIRC and higher tumor expression in LIHC, CHOL, COAD and BRCA. The THCA box plot shows higher CBX3P4 RNA expression in normal versus tumor tissue (log2 FC = −0.280, t-test p < 0.001).
This table shows molecular features associated with CBX3P4 in patient tissues and cancer cell lines. In patient samples, CBX3P4 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
